We have previously shown that peripheral artery disease (PAD) is associated with marked impairment of endothelial function (EF). Given that poor EF is associated with functional status of PAD patients as well as with increased morbidity and mortality in patients undergoing vascular procedures, determination of factors associated with poor EF in a PAD cohort is important. We hypothesized that decreased kidney function is associated with impaired EF in patients with PAD. Methods: This was a cross-sectional study of PAD patients presenting to a vascular surgery outpatient clinic at the San Francisco Veterans Affairs Medical Center including patients enrolled in the OMEGA-PAD I trial (NCT01310270) and the OMEGA-PAD Cohort. Brachial artery flow-mediated vasodilation was performed to assess EF. Kidney function was characterized by estimated glomerular filtration rate with the abbreviated Modification of Diet in Renal Disease formula. Linear regression was performed to assess the relationship between EF and kidney function in claudicants. Results: Ninety-seven patients with intermittent claudication participated in this study. Mean age was 69 6 8 years, 97% were male, and 79% were white. Comorbidities included hypertension (91%), dyslipidemia (87%), coronary artery disease (42%), and diabetes mellitus (38%). Mean ankle-brachial index was 0.73 6 0.14 and mean flow-mediated vasodilation was 7.0% 6 3.8%, indicating impaired EF. Linear regression showed an association between kidney function and EF (by 10 mL/min/1.73 m 2 ; b, 0.12; confidence interval, 0.05-0.20; P [ .001). After multivariable regression adjusting for age, race, log tumor necrosis factor a, hypertension, dyslipidemia, and diabetes, estimated glomerular filtration rate remained significantly associated with EF (P [ .033). Conclusions: In patients with PAD, decreased kidney function is associated with endothelial dysfunction. Further longitudinal studies are needed to better understand the impact of kidney function on PAD progression and the role of endothelial dysfunction in this process. (J Vasc Surg 2014;60:1605-11.) 
Nearly one third of patients aged 70 years and older will suffer from peripheral artery disease (PAD), 1 which can significantly affect quality of life and longevity. Despite available medical and surgical therapies, patients with PAD continue to have a higher risk of cardiovascular (CV) events, such as stroke or coronary ischemia, compared with patients with coronary artery disease (CAD). 2 Endothelial dysfunction is an early step in the development of atherosclerosis, and several studies have demonstrated that patients with PAD have diminished endothelial function (EF). 3, 4 We have previously shown that endothelial dysfunction, as measured by flow-mediated vasodilation (FMD) of the brachial artery, is associated with walking disability in PAD patients. 3 Impaired brachial artery FMD also has been shown to independently predict CV events in patients undergoing vascular surgery. 5 Given that impaired EF is associated with decreased functional status and increased morbidity and mortality in patients with PAD, determination of factors associated with impaired EF in a PAD cohort is important. PAD patients often have other concomitant manifestations of atherosclerosis. The coprevalence of chronic kidney disease (CKD) and PAD is high. 6 Impaired kidney function is an accepted risk factor for CV disease, and even mild stages of CKD have been associated with adverse CV events. 7, 8 For example, patients with stage 3 CKD have a 17% increase in mortality and those with stage 5 CKD have a 600% increase in mortality compared with an agematched population with normal kidney function. 7 Current evidence suggests that not only is decreased kidney function an independent predictor of CV events, it may also be a stronger predictor than traditional risk factors. 9, 10 In the setting of PAD, the presence of kidney disease predicts worse outcomes after peripheral revascularization. 11 Kidney disease is known to produce a state of oxidative stress and inflammation, 12 both of which are strong depressors of EF. Whether a relationship exists between kidney function and EF in a PAD cohort has not been established. The current study examined the determinants of endothelial dysfunction, including kidney function, in patients with PAD. We hypothesized that kidney function could be an important determinant of EF in patients with PAD.
METHODS

Study population and protocol
This cross-sectional study investigated the relationship between kidney function and EF in PAD patients. The investigator-initiated protocol was approved by the University of California, San Francisco, Committee on Human Research, and all patients gave informed consent. Patients referred to the outpatient vascular surgery clinic of the San Francisco Veterans Affairs Medical Center (SFVAMC) for evaluation of PAD were recruited. We included baseline data from patients enrolled into the OMEGA-PAD trial (NCT01310270) and the OMEGA-PAD Cohort. 13 Subjects were enrolled if they had at least one of the following inclusion criteria: intermittent claudication associated with an ankle-brachial index (ABI) < 0.9, toe pressures < 70 mm Hg, or imaging confirming $50% stenosis in the lower extremity arteries. Intermittent claudication was diagnosed on the basis of fatigue, discomfort, or pain that occurs in specific limb muscle groups during effort due to exerciseinduced ischemia. 14 Exclusion criteria included end-stage renal disease (ESRD) initiated on hemodialysis, significant hepatic or inflammatory disease, concurrent severe infections, acute illness or other major surgery within 30 days, and taking immunosuppressive medications. We recorded demographic and anthropometric data, CV history, risk factors, concurrent medications, and pertinent CV examination findings. EF was measured by brachial artery FMD, and kidney function was measured by estimated glomerular filtration rate (eGFR). Other measurements included lipid markers, metabolic markers, inflammatory markers, omega index, blood pressure, and bilateral ABIs.
Measurements
Demographic and anthropometric data, hemodynamic measurements, and walking distance. Demographic and anthropometric data collected included age, race, gender, hip and waist circumference, body mass index, prior supplement use, and exercise frequency. We collected CV history, such as CAD, cerebrovascular disease, and previous lower extremity vascular procedures, as well as risk factors including hypertension, diabetes mellitus type 1 and 2, hyperlipidemia, and tobacco use based on problem list and patient inquiry. Concurrent medications, pertinent CV examination findings, and blood pressure were also recorded. Walking distance and Rutherford classification were based on the patient's self-report during clinic visit, recorded by the investigator-vascular surgeons.
Vascular reactivity of brachial arteries. Flow-mediated endothelium-dependent vasodilation was performed according to current guidelines and standards previously described by our group. 3, 13, [15] [16] [17] Subjects were asked to fast and to abstain from nicotine and caffeine before the examination. A history of recent medications was recorded. Subjects were allowed to rest for 10 minutes in a supine position . Baseline blood flow velocity was recorded with an insonation angle of 60 degrees. The blood pressure cuff was inflated to the greater of 250 mm Hg or 50 mm Hg above the subject's systolic blood pressure for a period of 5 minutes.
Diameter and blood flow velocity were recorded until 3 minutes after cuff release. Analysis of the images was performed with continuous edge-detection software (Brachial Analyzer; Medical Imaging Applications LLC). Baseline diameter was recorded as the mean of 60 seconds of data. Hyperemia diameter was calculated by a predetermined time window of 55 to 65 seconds after cuff release. FMD% was calculated as (60s hyperemia diameter À Avg Baseline diameter/Avg Baseline diameter)*100.
Time-averaged velocity measurements were obtained by the peak velocity method. Average velocity at baseline was obtained from 60 seconds of data. Velocity of the hyperemia stimulus was calculated as the mean velocity of the first four heart beats after cuff release. Both mean velocity and the velocity-time integral were recorded. Flow was calculated by multiplying the time-averaged velocity by the brachial cross-sectional area.
Quality control was assessed at each point of the measurements. Image quality was evaluated by a second person and graded on a 6-point scale that includes registration structure (landmark), horizontally directed artery, correct longitudinal alignment, clearly visualized near-wall intimal-medial thickness and far-wall intimal-medial thickness, and at least 5 mm of clearly visualized artery. The interobserver variability in our laboratory is 0.05% 6 0.16%, and the intraobserver variability is 0% 6 0.15%.
Kidney function. Blood samples were collected in a fasting state for measurement of creatinine, and eGFR was calculated with the abbreviated Modification of Diet in Renal Disease formula based on age, gender, race, and serum creatinine level. 18 Plasma was assayed for these analytes on the same day as collection by the SFVAMC laboratory per standard methodology (Beckman Coulter Analyzer; Beckman Coulter, Inc, Miami, Fla). Subjects with eGFR > 90 mL/min/1.73 m 2 were assumed to be CKD stage 1 because of the presence of PAD, although the subjects did not necessarily have the confirmatory kidney damage, such as pathologic abnormalities or markers of damage, including abnormalities in blood or urine tests or imaging studies as set forth by the Kidney Disease Outcomes Quality Initiative guidelines from the National Kidney Foundation. 19 ABI. The ABI was measured by current guidelines and standards. 20 Systolic blood pressures of the brachial, posterior tibial, and dorsalis pedis arteries were measured bilaterally. For each lower extremity, the highest systolic pressure of the two pedal pulses was divided by the highest systolic pressure of the two brachial arteries.
Lipid, metabolic, and inflammatory measurements. Blood samples were collected in a fasting state for measurement of albumin, total cholesterol, triglycerides, low-density lipoprotein, high-density lipoprotein, highsensitivity C-reactive protein, interleukin-6, soluble intercellular adhesion molecule 1, tumor necrosis factor a (TNF-a), and hemoglobin A 1c . Plasma was assayed for albumin, total cholesterol, triglycerides, low-density lipoprotein, highdensity lipoprotein, high-sensitivity C-reactive protein, and hemoglobin A 1c on the same day as collection by the SFVAMC laboratory per standard methodology (Beckman Coulter Analyzer). The coefficient of variation for highsensitivity C-reactive protein with this procedure is 5.1%. Serum was isolated at the same time points for homocysteine and assayed the same day as collection by the SFVAMC laboratory per standard methodology (Architect i1000 Analyzer; Abbott Diagnostics, Lake Forest, Ill). Serum was processed per standard protocol and stored at À80 C until assayed for interleukin-6, soluble intercellular adhesion molecule 1, and TNF-a per standard kit protocol (R&D Systems Inc, Minneapolis, Minn). The typical coefficients of variation for interleukin-6, soluble intercellular adhesion molecule 1, and TNF-a are 7.4%, 4.6%, and 5.4%, respectively. The lower limits of detection are 0.04 pg/mL, 0.1 ng/mL, and 0.11 pg/mL, respectively.
Statistical analysis
For descriptive purposes, we categorized participants by FMD tertiles. Inflammatory markers not normally distributed were log-transformed. Differences in characteristics among FMD tertiles were compared by analysis of variance for continuous variables and Fisher exact test for dichotomous variables. For the overall regression models, patients were divided into FMD tertiles. We used linear regression models to examine the relationship between all variables listed in Table I and FMD tertiles. eGFR was treated as a continuous linear variable in the regression models; graphical diagnostics such as spline regression plots supported this decision. Multivariate adjustment was made for demographic characteristics and traditional CV risk factors on the basis of an a priori determination of P < .1 in univariate models. An a priori determination of significance at P < .05 was used in the multivariate model. Statistical analyses were performed with Stata/SE 12 (StataCorp, College Station, Tex).
RESULTS
A total of 97 patients with intermittent claudication participated in this study. Tables I and II demonstrate the demographics, comorbidities, medications, and PAD risk factors by FMD tertiles. The mean age was 69 6 8 years, 97% were male, and 79% were white. Comorbidities included hypertension (91%), dyslipidemia (87%), CAD (42%), and diabetes mellitus (38%). Mean eGFR was 74 6 21 mL/min/1.73 m 2 , and mean index ABI was 0.73 6 0.14. Mean FMD was 7.0% 6 3.8% (Table III) , indicating impaired EF compared with the normal range of 10% to 13%. 21 With decreased kidney function, there was a decrease in FMD (I: 65, II: 74, III: 82 mL/min/ 1.73 m 2 ; P ¼ .012; Fig) .
By univariate analysis ( 95% CI, 0.05-0.20; P ¼ .001) were associated with EF. After multivariate linear regression adjusting for age, race, log TNF-a, and hypertension, only eGFR remained significantly associated with FMD (P ¼ .033; Table IV ). A decrease of 10 mL/min/1.73 m 2 in eGFR was associated with a 0.12% decrease in FMD with a 95% CI of 0.008 to 0.193.
DISCUSSION
In a cross-sectional cohort study of patients presenting to our outpatient vascular surgery clinic with PAD, we found a significant association between kidney function and EF as measured by brachial artery FMD in patients with PAD. Among PAD patients with claudication, those with CKD have the worst EF. In view of the high risk associated with PAD, 2 a better understanding of the relationship between kidney function and endothelial dysfunction could be clinically relevant.
Factors influencing EF. Traditional risk factors for atherosclerosis, including diabetes, hyperhomocysteinemia, hypertension, dyslipidemia, and smoking, are also known to affect EF. [22] [23] [24] [25] [26] Our analysis suggests that kidney disease may be a particularly strong and independent risk factor for endothelial dysfunction in the PAD population.
Several clinical studies have explored the relationship between kidney failure and endothelial dysfunction. Nakamura et al 27 found that EF assessed by brachial FMD was associated with kidney disease in patients with CAD. They also suggested that systemic EF may precede the development of kidney disease in patients with normal kidney function. In a cohort of patients with essential hypertension, Perticone et al 28 found an impaired vasodilatory response to acetylcholine associated with moderate kidney disease. Kari et al 29 found lower brachial FMD, higher endothelial nitric oxide synthase inhibitors, and lower nitric oxide metabolites in a small nonatherosclerotic cohort of 23 children with CKD. An ESRD cohort of 44 subjects on hemodialysis for at least 3 months was compared with 25 controls, showing that ESRD is associated with lower shear stress, compliance, and brachial FMD by the hand-warming technique. 30 Wever et al 31 found endothelial dysfunction as assessed by diminished whole body nitric oxide production in seven CKD patients compared with seven controls. Kidney function and EF have been associated in various CAD and CKD populations with varying techniques of evaluating EF. Nevertheless, this relationship has not been studied in the PAD population.
Mechanisms of endothelial dysfunction in kidney disease. Endothelial dysfunction is considered to be a systemic issue. In glomerular endothelial cells, albuminuria leads to a reduction in the endothelium-dependent vascular relaxation response in the kidney. 32 Whether kidney endothelial dysfunction precedes systemic EF, or vice versa, is controversial. 27 The key markers responsible for this cascade between kidney and systemic endothelial dysfunction are likewise unclear. Potential mediators between kidney function and EF include asymmetric dimethylarginine (ADMA) and TNF-a.
Kidney failure permits an accumulation of competitive inhibitors of endothelial nitric oxide synthase, namely, ADMA. 33 ADMA is raised in ESRD and could contribute to higher CV risk in patients with chronic kidney failure. 33 Studies show that elevated ADMA levels are associated with EF assessed by brachial FMD in patients with PAD 34 and independently predict arterial stiffness. 26 Elevated ADMA concentrations predict progression of both CKD and PAD. 35 ADMA accumulation leads to increased production of inflammatory markers such as TNF-a and interleukin-6 and interleukin-8 as well as the binding of monocytes to endothelial cells. 33 Furthermore, inflammation inhibits the enzyme that degrades ADMA, contributing to a vicious circle of ADMA accumulation and increased inflammation. 33 It is therefore not surprising that our study suggests that TNF-a, a well-known marker of inflammation, may play a role as a link between EF, CKD, and PAD. TNF-a is associated with greater incidence of PAD and is known to act independently on human endothelial cells. 2, 36 TNF-a also predicts mortality in acute kidney failure and progression to ESRD. 37 The median TNF-a in our cohort was 2.11 pg/mL (interquartile range, 1.68-2.47), which is higher than normal levels around 1.81 pg/mL (interquartile range, 1.29-2.33). 38 Our univariate analysis supports EF as an inflammatory process, showing an association with log TNF-a. However, it is currently uncertain whether TNF-a is specifically involved in the pathway for CKD. 37 Further studies need to be done to identify the role of TNF-a in CKD and PAD.
Clinical implications. Studies have shown that decreased kidney function is an independent and significant predictor of outcomes in patients after peripheral revascularization. 11 Kidney function has increasingly displayed greater predictive value of CV events in patients with atherosclerosis than traditional risk factors. 9,10 Kidney failure patients have extremely low FMD, even more so than that of PAD patients. 29 Once advanced kidney disease is present, it may contribute to the progression of systemic endothelial dysfunction more than traditional CV risk factors do.
To our knowledge, this report is the first to examine the relationship between kidney function and EF evaluated by brachial artery FMD in a PAD cohort. Several studies have found impaired vasodilatory response to be associated with loss of kidney function in other cohorts or with techniques other than brachial artery FMD through reactive hyperemia. [27] [28] [29] [30] [31] Because several studies have characterized impaired EF in the ESRD population requiring hemodialysis, we focused on earlier stages of CKD and were able to detect an association. We therefore confirm through this cross-sectional study that kidney function could serve as a strong risk marker for EF in PAD patients with intermittent claudication. This cohort will continue to be observed longitudinally to determine if there is an association between kidney function and EF over time.
Limitations. The patient population studied was not representative of the wider PAD population as it included only veterans who were mostly male and white referred to a vascular surgery clinic at the SFVAMC. This study does not address the majority of patients with PADdthose who are asymptomatic. Likewise, it also does not examine the most severe end of the PAD spectrum, critical limb ischemia. Although patients were evaluated for PAD, FMD was assessed not in the lower extremity but in the brachial artery. Nevertheless, Anderson et al 39 found that brachial FMD modeled FMD in the coronary arteries as well, indicating that brachial FMD is predictive of systemic EF. Whereas a history of recent antihypertensive and antiplatelet medications was recorded, cilostazol and nitrates were not included. In addition, walking distance was assessed on the basis of subjective self-report, rendering a large error within each FMD tertile. We are currently adding the 6-minute walk test to better understand the relationship between walking and EF. Furthermore, the population studied may be skewed compared with the typical PAD patient with regard to the psychological profile of patients, affecting overall stress and inflammation. 40 Although the sample size is modest, it is larger than all but one trial studying the effects of kidney disease on EF as assessed by FMD. Most important, this report does not imply causation but rather an association.
CONCLUSIONS
In patients with PAD and claudication, those with CKD have the worst endothelial dysfunction as measured by FMD. As such, kidney function is as important a risk factor as traditional PAD risk factors. Longitudinal studies are needed to explore the relationship between declining kidney function and progression of PAD over time and whether these are both associated with or driven by progressive impairments in EF.
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